Tectonic Therapeutic, Inc. (TECX) Market Cap
Tectonic Therapeutic, Inc. has a market capitalization of $535.1M.
Financials based on reported quarter end 2025-12-31
Price: $28.50
▲ 0.86 (3.11%)
Market Cap: 535.13M
NASDAQ · time unavailable
CEO: Alise S. Reicin
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2018-06-21
Website: https://tectonictx.com
Tectonic Therapeutic, Inc. (TECX) - Company Information
Market Cap: 535.13M · Sector: Healthcare
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Analyst Sentiment
Based on 4 ratings
Analyst 1Y Forecast: $67.50
Average target (based on 1 sources)
Consensus Price Target
Low
$60
Median
$68
High
$75
Average
$68
Potential Upside: 136.8%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"TECX reported zero revenue, indicating it is in a pre-revenue phase. The company has a net loss of $19.226M and a negative operating cash flow of $14.461M. Total assets stand at $261.038M against liabilities of $9.709M, resulting in significant net debt of -$252.522M, indicating a strong cash position. The stock price is currently at $30.07, with a notable 1-year price change of 40.51%, reflecting investor confidence amid its operational challenges. The company shows growth potential given the 6-month price increase of 99.01%. However, the lack of revenue and ongoing losses pose risks. Overall, while TECX shows promise in market performance, its fundamentals highlight significant weaknesses that should be monitored closely as the company progresses."
Revenue Growth
The company is pre-revenue.
Profitability
Net income is negative at -$19.226M.
Cash Flow Quality
Negative operating cash flow of -$14.461M.
Leverage & Balance Sheet
Strong balance sheet with net debt of -$252.522M.
Shareholder Returns
1-year price increase of 40.51% indicates strong market interest.
Analyst Sentiment & Valuation
Price target stability at $60 suggests a positive outlook despite risks.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.